Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

diphosphonates
metastasis
castration-resistant prostate cancer
soft tissue disease
bone scan
  • 0 views
  • 19 Feb, 2024
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

platelet count
testosterone
metastasis
orchiectomy
liver metastasis
  • 0 views
  • 19 Feb, 2024
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)

This increasingly allows individualized specific therapy of patients with prostate cancer recurrence. PSMA PET has now been included in national and international guidelines for the diagnosis of patients with biochemical recurrence of prostate cancer.

cancer recurrence
positron emission tomography
local therapy
metastasis
molecular imaging
  • 0 views
  • 19 Feb, 2024
Lutetium-177-PSMA-I&T in Oligo-metastatic Hormone Sensitive Prostate Cancer

  Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells.

white blood cell count
hormone therapy
endocrine therapy
platelet count
testosterone
  • 4 views
  • 19 Feb, 2024
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires and corresponding …

external beam radiation therapy
positron emission tomography
prostate cancer metastatic
pet/ct scan
adenocarcinoma of prostate
  • 0 views
  • 19 Feb, 2024
EBRT and HDR Brachytherapy for Unfavorable-intermediate High and Very High-risk Prostate Cancer

This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects. This study is also looking at patient outcomes, quality of life, …

external beam radiation therapy
androgen suppression
digital rectal examination
adenocarcinoma of prostate
prostate adenocarcinoma
  • 0 views
  • 19 Feb, 2024
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

In this research study, is assessing the feasibility of using an MR-guided implantable microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants that have prostate cancer and are scheduled for a radical prostatectomy. The name of the study intervention involved in this study is: Implantation …

neutrophil count
carcinoma
prostatectomy
  • 2 views
  • 19 Feb, 2024
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

This is a prospective, open-label, randomized, controlled, cross-over trial assessing patient preference for apalutamide versus enzalutamide in 146 male patients with recurrent or metastatic hormone-sensitive prostate cancer. The primary objective is to investigate whether there is any difference in patient preference between apalutamide and enzalutamide in patients with recurrent or …

prostate cancer
adenocarcinoma
androgens
adenocarcinoma of prostate
apalutamide
  • 0 views
  • 19 Feb, 2024
Diffusion Basis Spectrum Imaging of the Prostate

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

prostate cancer screening
biopsy of prostate
  • 0 views
  • 19 Feb, 2024
HDR Brachytherapy 68-Ga-RM2 PET 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)

local therapy
pet/mri
brachytherapy
  • 0 views
  • 19 Feb, 2024